SOLARA PHARMA (SOLR) Surges 14% on ₹9.6 Cr Q4 Profit; Revenue Soars 42% YoY

Solara Active Pharma Sciences reported a sharp earnings turnaround in Q4 FY26 as the company posted a net profit of ₹9.6 crore against a loss of nearly ₹142 crore in the year-ago quarter. The strong recovery immediately lifted investor sentiment, pushing SOLARA PHARMA shares up nearly 14 percent intraday toward the ₹700 level. Revenue from operations jumped 42 percent year on year to around ₹395 crore, supported by higher Active Pharmaceutical Ingredient sales and better utilization across manufacturing plants. The earnings improvement was also backed by lower operating costs and a recovery in export demand from regulated markets, including the United States and Europe.

₹395 Cr Revenue, Better Margins, Higher API Demand: What Changed for SOLARA PHARMA?

The biggest positive for investors was not just the profit figure, but the pace of revenue expansion and margin recovery during the quarter. EBITDA margins improved as input cost pressure eased compared to previous quarters, helping the company improve operational efficiency after a difficult FY25. SOLARA PHARMA’s specialty API business witnessed stronger traction, particularly in pain management and anti-inflammatory product categories, which supported overall sales growth. According to market discussions covered by Business Standard, analysts believe stable export demand and tighter cost control may continue supporting earnings recovery in FY27. 

SOLARA PHARMA Crosses ₹650 Breakout Zone as Volumes Spike

SOLARA PHARMA crossed the important ₹650 resistance level during Thursday’s session, which traders viewed as a major technical breakout after months of weak price movement. The stock traded between ₹680 and ₹710 levels during the day, while volumes surged sharply above normal averages, indicating fresh institutional accumulation rather than short covering activity. Market capitalization moved close to the ₹3,000 crore mark after the rally, reflecting renewed confidence in the company’s turnaround strategy. 

Conclusion

SOLARA PHARMA’s Q4 FY26 performance marked one of the strongest earnings recoveries in the mid-cap pharma segment this quarter. A move from heavy losses to profitability, combined with 42 percent revenue growth and improving margins, significantly changed market sentiment around the stock. Investors will now closely watch whether the company can maintain export growth, improve cash flow, and sustain margins in FY27.

FAQs

Disclaimer

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.